Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Prior treatment

• For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary

Other illness

• Dependency in basic activities of daily living (bADLs) due to cognitive impairment
• Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
• Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
• History of severe, clinically significant central nervous system trauma
• Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

• Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
• Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study